Topic: Rna Vaccines

Scientific journals like DVM 360 are reportedly discussing the use of aerosolized and ingestible vaccines for livestock, which critics fear will be transitioned to human populations. Attorney Tom Renz explains that "mRNA" in commercial shots actually stands for "modified RNA" (mod RNA), which is designed to persist in the body longer than natural messenger RNA. There are also concerns that manufacturing defects have left significant DNA loads in vaccine batches, potentially altering human genetics.

Mikovits asserts that no vaccine has ever undergone a proper safety study since the 1986 National Childhood Vaccine Injury Act. She characterizes the current medical agenda as "premeditated murder" and genocide. She warns that the push for cremation is a tactic to destroy biological evidence of vaccine-induced damage and synthetic viral sequences.

Dr. Peter McCullough discusses DARPA's 2012 "Adept Protect P3" program, which aimed to develop gene-encoded vaccines to stop pandemics within 60 days. McCullough argues that these vaccines were not a rapid response to Wuhan but a long-planned military technology. He calls for all COVID-19 vaccines to be pulled from the market and for the establishment of vaccine injury centers of excellence.

Dr. Peter McCullough discusses research by Sasha Latypova regarding "hot lots" of vaccines that show higher rates of injury and death. He suggests that many people who remained unharmed after the shot may have received degraded messenger RNA due to improper handling or storage. A theory is proposed that conservative states may have had higher death rates because they were more efficient at maintaining the cold chain for the "toxic" product.

A brief segment features a clip discussing the transition from traditional egg-based vaccine production to disruptive, iterative technologies. The speaker suggests that a novel avian virus outbreak in China could lead to a system where RNA sequences are beamed to local centers, allowing individuals to print and self-administer vaccine patches at home.

The discussion explores why RNA technology was never successfully brought to market before COVID-19, citing past failures due to severe autoimmune responses. Rappaport argues that the current vaccines were only designed to prevent mild symptoms like coughs, rather than serious illness or transmission.